Fracture Risk Reduction Greater With Denosumab vs Alendronate, According to Real-World Data
Treatment with Prolia was associated with greater reductions in the overall relative risk across various fracture types.
Diagnosis & Disease Information
Turalio Dosing Regimen Updated for Tenosynovial Giant Cell Tumor
A new dosing regimen for Turalio® (pexidartinib) is now available for the treatment of adults with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery. The recommended dose of Turalio is now 250mg orally twice daily (taken as two 125mg capsules) with a low-fat meal…
Denosumab Biosimilar for Osteoporosis, Other Conditions Under FDA Review
The BLA is supported by a comprehensive data package that includes data from the phase 1/3 ROSALIA study.
FDA: Prolia Use in Dialysis Patients May Cause Severe Hypocalcemia
According to a long-term safety study and a separate FDA internal study, Prolia had an increased risk of hypocalcemia in patients with advanced kidney disease on dialysis.
Gentamicin-Eluting Bone Graft Substitute Gets FDA Clearance
Cerament G is a resorbable, gentamicin-eluting ceramic bone void filler.
Abaloparatide Looks Promising for Men With Osteoporosis
The phase 3 ATOM study evaluated the efficacy and safety of abaloparatide in 228 men with osteoporosis.
Tymlos Label Update Highlights Bone Building Mechanism of Action
The update is based on data from an open-label, single-arm histomorphometry study.
Osteoporosis Treatments Compared to Assess Effects on Bone Mineral Density
The network meta-analysis compared the effects of 9 osteoporosis drugs on BMD.
- Loading...
Loading...
Loading... 
Loading...